Organoid Sciences

What Organoid Sciences does

Organoid Sciences (KOSDAQ: 476040), founded in 2018 and headquartered in Cheongju-si, South Korea, is a clinical-stage biotechnology company built on proprietary organoid-based 3D stem cell culture technology. The company operates a platform-plus-products architecture anchored on its core ORGAN-OID technology, which produces three-dimensional organ-like structures that replicate the architecture and function of real organs using adult stem cells, with proprietary methods delivering intestinal organoids containing over four times the stem cell content of native human tissue. Organoid Sciences commercializes two principal product lines: ATORM, a regenerative therapeutics platform with clinical-stage assets including ATORM-C (refractory inflammatory bowel disease, EMA ATMP-certified), ATORM-S (salivary gland hypofunction), and pipeline programs ATORM-E (endometrium) and ATORM-L (liver); and ODISEI, an organoid-based preclinical drug evaluation solution with modules spanning oncology (ONC), gut (GUT), skin (SKIN), renal (NEP), CNS, liver (HEP), infectious disease (VIR), companion animal (PET), and spatial biology (Spatial, using CODEX multiplex-IHC for 100+ biomarkers). A complementary PODOTX platform offers immunotherapy sensitivity evaluation.

The company operates a B2B enterprise sales model targeting pharmaceutical and biotechnology companies, cosmetics firms, research institutions, and medical centers in South Korea, with a stated plan for global commercialization in 2028. Revenue mechanics combine recurring ODISEI evaluation services (commercial since 2021) with future ATORM prescription revenue (planned from 2027 domestically), CDMO services, and organoid research products. Named customers include Astellas Pharma, LG Chem, JW Pharmaceutical, ABL Bio, Genome & Company, Abion, Cha Biopharm, ImmuneOncia, Cosmax, Autotelic, and NeoRegen. Organoid Sciences reported KRW 4 billion (~$3M USD) in ODISEI revenue in 2025 with a company-stated target of approximately KRW 30 billion (~$22M) by 2028, and the company has raised approximately KRW 48-49 billion cumulatively across Series A, Series B, and follow-on rounds before its 2025 KOSDAQ listing under technology special exception. Manufacturing is anchored by an operational Gwangmyeong GMP Center and a Seoul Asan Medical Center GMP Center under construction through October 2025.

Name

Organoid Sciences

Legal name

오가노이드사이언스 주식회사 (ORGANOIDSCIENCES Inc.)

Website

https://organoidrx.com

Company type

Public

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Short description

Organoid Sciences is a South Korean clinical-stage biotech that builds organoid-based 3D stem cell platforms for regenerative therapeutics (ATORM) and preclinical drug evaluation services (ODISEI), serving pharmaceutical, biotechnology, cosmetics, and academic customers.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Services

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industries

Stem Cell–Based Regenerative Therapies (HLAAAGAA), Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy CDMO (Autologous/Allogeneic Manufacturing) (HLAGAGAA)

Keywords

• Organoid drug screening
• Regenerative medicine therapeutics
• Preclinical drug evaluation
• Patient-derived organoids
• Spatial biology analysis

Headquarters

HQ city

Seongnam

HQ country

South Korea

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

1. ODISEI evaluation solutions: Organoid-based drug efficacy and toxicity evaluation solutions commercially available since 2021. Revenue from providing evaluation services to pharmaceutical and biotech companies for drug screening and preclinical testing.
2. ATORM regenerative therapeutics: Organoid-based regenerative medicine products. Expected to generate revenue from medical institution prescriptions starting 2027 domestically and 2028 globally. Clinical stage with advanced regenerative medicine pathway.
3. CDMO services: Contract manufacturing for cell therapy products and organoid-based research products for organoid cultivation
4. Organoid research products: Research products for organoid cultivation sold to research institutions and pharmaceutical companies

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Organoid Sciences develops and commercializes organoid-based regenerative therapeutics (ATORM platform with intestinal, salivary gland, endometrium, and liver variants) and organoid-based drug efficacy/toxicity evaluation solutions (ODISEI platform with oncology, gut, skin, infectious disease, renal, CNS, liver, spatial biology, and companion animal modules). The company also provides PODOTX immunotherapy sensitivity evaluation, organoid research products, and CDMO services for cell therapy manufacturing, all built on proprietary 3D adult stem cell organoid technology.

Product overview

OrganoidSciences operates as a platform-plus-products architecture built on its core ORGAN-OID technology, a 3D stem cell culture platform that recreates human organ structure and function. The company offers two main product lines: ATORM (organoid-based regenerative therapeutics including ATORM-C for intestinal, ATORM-S for salivary gland, ATORM-E for endometrium, and ATORM-L for liver applications) and ODISEI (organoid-based evaluation solutions with specialized modules for oncology, gut, skin, companion animals, infectious diseases, renal diseases, brain diseases, liver diseases, and spatial biology). Additional offerings include PODOTX for immunotherapy sensitivity evaluation. ATORM provides regenerative therapeutic treatments while ODISEI enables preclinical drug efficacy and toxicity testing without animal testing.

Differentiator

Problem solved

Functional benefit

Brands

• ATORM: Organoid-based regenerative therapeutics platform for treating various diseases including intestinal (ATORM-C), salivary gland (ATORM-S), endometrium (ATORM-E), and liver (ATORM-L) conditions
• ODISEI
• PODOTX

Products and services

• ATORM Regenerative Therapeutics Platform Organoid-based regenerative therapeutics platform providing fundamental treatments for diseases difficult to address with conventional pharmaceuticals, using therapeutics based on direct regenerative mechanisms derived from adult stem cell-derived organoids. The platform includes ATORM-C (intestinal, EMA ATMP certified), ATORM-S (salivary gland), ATORM-E (endometrium), and ATORM-L (liver) variants.
• ODISEI Drug Evaluation Solution Organoid-based drug efficacy and toxicity evaluation solution that provides animal-free testing methods to address skyrocketing drug development costs, lack of preclinical evaluation models for new modality drugs, and regulatory policies by FDA and EMA to minimize animal testing. Includes modules for oncology (ODISEI ONC), gut (ODISEI GUT), skin (ODISEI SKIN), companion animals (ODISEI PET), infectious disease (ODISEI VIR), renal (ODISEI NEP), CNS (ODISEI CNS), liver (ODISEI HEP), and spatial biology (ODISEI Spatial).
• PODOTX Immunotherapy Sensitivity Evaluation Platform (Polaris) Immunotherapy sensitivity evaluation platform (Polaris) for predicting patient response to immunotherapeutic agents with high sensitivity, specificity, and accuracy, reflecting individual patient characteristics using organoid-based evaluation.
• CDMO Services for Cell Therapy and Organoid Manufacturing Contract manufacturing services for cell therapy products and organoid-based research products, provided through GMP-certified facilities (Gwangmyeong GMP Center with 825 m² and 4 manufacturing suites, plus the planned Seoul Asan Medical Center GMP Center with 560 m² and 2 manufacturing suites).
• Organoid Research Products for Cultivation Research products and consumables for organoid cultivation sold to research institutions, universities, and pharmaceutical companies, enabling experimental efficiency and shortening of experimental times in organoid-based research.

Quantifiable outcome

• Stem cell content 4x higher than native human tissue
• +3 more outcomes

Named customers11 records

Segments6 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability6 records

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and supporting.

• BioDcoreStrategic or Co-development Partner · 12 March 2026Collaboration to develop organoid-based infectious disease response platform in South Korea. Platform aims to shorten experimental times and improve research efficiency for zoonotic infectious diseases like avian influenza and COVID-19.
• Jeonbuk National UniversitycoreStrategic or Co-development Partner · 12 March 2026Collaboration with BioD and Organoid Science to develop organoid-based infectious disease response platform. Aims to speed up pandemic preparedness through improved research efficiency.
• Lambda Biologics GmbHcoreStrategic or Co-development Partner · 1 January 2023Partnership established through VOS DISCOVERY for organoid development and commercialization activities
• PODO Therapeutics (Severance Hospital Joint Venture)coreStrategic or Co-development Partner · 1 January 2022Joint venture established with Severance Hospital for organoid therapeutic development and commercialization
• Seoul Asan Medical CentercoreStrategic or Co-development Partner · 1 June 2021R&D collaboration agreement signed; GMP center established within Biomedical Research Institute; clinical trials for ATORM-C conducted
• Korea Research Institute of Bioscience and Biotechnology (KRIBB)supportingStrategic or Co-development PartnerAdvisory on organoid R&D and new material evaluation solutions enhancement through Stem Cell Convergence Research Center
• International clinical trial partners (Mount Sinai NY, UKSH, Mahidol University, UKD)coreStrategic or Co-development PartnerGlobal clinical trial infrastructure partners for ATORM-C multinational Phase 2 trials planned for 2028

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Hubrecht Organoid Technology (HUB): Pioneer organoid biobank and drug screening services founded by Hans Clevers; offers patient-derived organoid disease models for preclinical efficacy testing directly overlapping ODISEI's core evaluation offering.
• Crown Bioscience (Charles River Laboratories): Global leader in oncology drug evaluation services including 3D/organoid and PDX platforms, now part of Charles River Labs; most direct competitor for ODISEI ONC and PDO biobank offerings.
• CN Bio Innovations: Develops organ-on-chip and microphysiological systems for drug discovery and toxicity testing, overlapping directly with ODISEI's preclinical evaluation value proposition across multiple organ modules.
• InSphero: Provides 3D microtissue and organoid platforms for preclinical drug efficacy and safety testing; competes in the same animal-free drug evaluation category as ODISEI.
• REPROCELL: Stem cell and organoid-based services for drug discovery and clinical diagnostics; offers biobanking and iPSC-derived organoids that overlap with ODISEI's evaluation and ODISEI SKIN modules.
• MEDIPOST: Korean stem cell therapy company with approved Cartistem product for cartilage regeneration; competes in the same Korean regenerative medicine commercial landscape as ATORM, and the CMO previously led MEDIPOST's foreign product development team.
• Corestem (CorestemChemon): Korean stem cell therapy company with approved Neuronata-R for ALS and pipeline in autoimmune indications; overlaps with Organoid Sciences' regenerative medicine ambitions and competes for similar Korean reimbursement and hospital channels.

Broad incumbents

• Molecular Devices (Danaher): Subsidiary of Danaher providing high-content screening, 3D cell imaging, and laboratory automation for drug discovery including organoid workflows; larger incumbent with broader life sciences portfolio overlapping ODISEI's evaluation tools.
• STEMCELL Technologies: Established supplier of organoid culture reagents, tools, and contract services for stem cell and organoid research; overlaps with Organoid Sciences' organoid research products and CDMO lines.

Emerging players

• DefiniGEN: iPSC-derived organoid and liver disease models for preclinical drug discovery; emerging player with overlapping offering in disease-specific organoid models used by pharma customers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/organoidsciences

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Organoid Sciences